Inventera Inc.
KOSDAQ-listed biotech developing an iron-based nano-MRI contrast agent on its polysaccharide nanostructure drug delivery platform, Invinity™.
As of 2026-10-11, Inventera Inc. has 4 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2018 and listed on KOSDAQ in 2026, Inventera is a biotech specializing in nanomedicine. It has developed its own polysaccharide-based nanostructure drug delivery platform, Invinity™, which controls surface charge and particle size to suppress protein corona formation and enable stable in-vivo dispersion and targeted delivery. Based on this platform, it is developing an iron (Fe)-based, disease-specific nano-MRI contrast agent intended to address the safety concerns of existing gadolinium (Gd)-based contrast agents.
Clinical trials
data.go.kr4 MFDS clinical trial authorisations · 2021–2025 (Phase 1/2a 2 · Phase 3 1 · Phase 2b 1)
- Phase 3NEMO-103주2025-06-17
9 trial sites
- Phase 1/2aINV-001주2023-11-15
2 trial sites
- Phase 2bNEMO-103주2023-03-29
3 trial sites
- Phase 1/2aNEMO-103주2021-04-02
1 trial site
Global clinical trials
ClinicalTrials.gov · sponsor-matchedPhase 3 · Active not recruiting · 2025-09 · NCT07057037
R&D and key agreements
Source: DART corporate disclosureInvinity™ · 플랫폼 기술 · Polysaccharide-based nanostructure drug delivery platform; controls surface charge and particle size to suppress protein corona formation and enable targeted delivery
철(Fe) 기반 나노-MRI 조영제 · Disease-specific contrast agent candidate addressing safety concerns of gadolinium-based agents
Key disclosures
KRX KIND via OpenDARTPublications
PubMed · affiliation-matched- Lymphatic‑specific magnetic resonance lymphangiography biomarkers for grading lymphedema in animal models.
Scientific reports · 2026-02 · Cheon H, Woo DC, Chae YJ 외 5
- Comparison of the Pharmacokinetics of Gadolinium-Based and Iron Oxide-Based Contrast Agents inside the Lymphatic Structure using Magnetic Resonance Lymphangiography.
Molecular imaging and biology · 2024-08 · Chae YJ, Kim KW, Kim MH 외 8
- Analysis on efficacy of magnetic resonance lymphangiography using INV-001 in healthy beagle dogs.
Scientific reports · 2024-05 · Jang JS, Kim N, Kim MH 외 5
- Ultrasmall Mn-doped iron oxide nanoparticles with dual hepatobiliary and renal clearances for T1 MR liver imaging.
Nanoscale advances · 2024-04 · Lee S, Byun A, Jo J 외 6
Patents
KIPRIS · applicant-matchedUS · Published · 2025-11 · Application 19388084
PCT · Published · 2025-10 · Application PCT/KR2025/017742
Published · 2025-10 · Application 1020250162106
PCT · Published · 2025-10 · Application PCT/KR2025/017118
Published · 2025-10 · Application 1020250156000
US · Published · 2025-05 · Application 19219697
PCT · Published · 2025-04 · Application PCT/KR2025/004884
Published · 2025-04 · Application 1020250046866
Published · 2025-03 · Application 1020250036585
Published · 2024-11 · Application 1020240173631
Show 18 more patents
US · Published · 2024-02 · Application 18437925
Published · 2024-02 · Application 1020240019819
EP · Published · 2024-02 · Application 24753679.0
EP · Published · 2024-02 · Application 24753680.8
EP · Published · 2024-02 · Application 24753712.9
PCT · Published · 2024-02 · Application PCT/KR2024/001958
PCT · Published · 2024-02 · Application PCT/KR2024/001953
PCT · Published · 2024-02 · Application PCT/KR2024/095103
Published · 2024-02 · Application 1020240019817
Published · 2024-02 · Application 1020240019818
Published · 2024-01 · Application 1020240003271
PCT · Published · 2023-12 · Application PCT/KR2023/021979
Registered · 2023-09 · Application 1020230129071
EP · Published · 2022-03 · Application 22855938.1
Published · 2022-03 · Application 1020220028969
Registered · 2018-07 · Application 1020180088177
US · Registered · 2017-02 · Application 15999746
Registered · 2014-01 · Application 1020187001516
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive2
- OpenAIOAI-SearchBot31
- PerplexityPerplexityBot6
- AnthropicClaudeBot2
- MicrosoftBingbot1
- GoogleGoogleOther1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 10, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Inventera Inc. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.
Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.
KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition